Inclusion of poly (ADP-ribose) polymerase inhibitors (PARPi) as standard therapy for non-mucinous high-grade epithelial ovarian cancer (EOC) led to mainstream, reflex germline and tumour BRCA1/2 testing [1]. The gene discussed is BRCA1; the disease is ovarian carcinoma.